Using current estimates of US long-COVID burden (assuming the probability of long COVID is 6% and symptoms last 1 year), cases cost an average of $2.01 billion annually. The economic burden of long ...

In the region's other developments, Sierra Leone reported more cases, with the first two linked to the clade 2 global strain.

A new experimental vaccine developed by researchers at MIT and Caltech could offer protection against emerging variants of SARS-CoV-2, as well as related coronaviruses, known as sarbecoviruses, that ...

Legislation that would block hospitals from transfusing blood containing COVID-19 antibodies or “synthetic mRNA” could have ...

Scientists have discovered a new type of anti-malarial antibody that doesn't interfere with current vaccines, at least in mouse models. Could they help eliminate malaria in the future?

This article explores how broadly neutralizing antibodies are being researched, not only for their potential in the ...

Researchers believe the innovative idea holds immense promise for tackling a wide range of diseases including cancer through ...

Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different ...

“The discovery that memory B cells and antibodies specific to [Nipah] persist 20 years post-infection suggests that vaccines ...

With a rapidly aging global population, there is an urgent need to address the unique healthcare challenges faced by older ...

Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus ...

CLAIM: HIV is part of the composition of COVID-19 vaccinesFACT: False. An experimental vaccine developed by Professor Keith ...